Kaplan, PBGücer, FSayin, NCYüce, MAYardim, T2024-06-122024-06-1220020024-77581943-3565https://hdl.handle.net/20.500.14551/23259OBJECTIVE: To evaluate the affects of an oral continuous and transdermal cyclic 17-beta estradiol and norethindrone acetate combination on platelet aggregation in postmenopausal women. STUDY DESIGN: Fifty postmenopausal women were randomly assigned to receive 17-beta estradiol and norethindrone acetate either orally continuously or transdermally cyclically and sequentially. Platelet counts and maximum platelet aggregation rates were measured before and after three months treatment. RESULTS: At three months there were no significant changes in platelet counts or in adenosine diphosphate-induced or epinephrine-induced platelet aggregation rates in either treatment group. CONCLUSION: Hormone replacement treatment with a 17-beta estradiol and norethindrone. acetate combination either orally continuously or transdermally cyclically and sequentially does not affect platelet aggregation in postmenopausal women.eninfo:eu-repo/semantics/closedAccessPostmenopausal Hormone ReplacementTherapyPostmenopausePlatelet AggregationCardiovascular Risk-FactorsVenous ThromboembolismEstrogensHeartMenopauseHormonesDiseaseUsersArticle478651655Q3WOS:00017765790001012216432